Man remains missing after a Swiss glacier collapsed and destroyed 90% of an Alpine village
The landslide sent plumes of dust skyward and coated with mud nearly all of an Alpine village that authorities had evacuated earlier this month as a precaution. State Councilor Stéphane Ganzer told Radio Télévision Suisse that 90% of the village was destroyed.
The Cantonal Police of Valais said that a search and rescue operation was underway for the man, whose name wasn't made public, and it involved a drone with a thermal camera.
The regional government said in a statement that a large chunk of the Birch Glacier above the village had broken off, causing the landslide, which also buried the nearby Lonza River bed, raising the possibility of dammed water flows.
Video on social media and Swiss television showed that the mudslide near Blatten, in the southern Lötschental valley, partially submerged homes and other buildings under a mass of brownish sludge.
In recent days, authorities had ordered the evacuation of about 300 people, as well as all livestock, from the village amid fears that the 1.5 million-cubic meter (52 million-cubic foot) glacier was at risk of collapse.
Swiss glaciologists have repeatedly expressed concerns about a thaw in recent years — attributed in large part to global warming — that has accelerated the retreat of glaciers in Switzerland.
The landlocked Alpine country has the most glaciers of any country in Europe, and saw 4% of its total glacier volume disappear in 2023. That was the second-biggest decline in a single year after a 6% drop in 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
4 hours ago
- CBS News
Florida father, son rescue family of 5 and their dog from sailboat fire
A family and their dog are safe thanks to the quick actions of a Jacksonville father and son who rescued them after their sailboat caught fire. On Sunday, Michael Shillingford and his 8-year-old son Vincent enjoyed a day on the water near Julington Creek and the St. John's River. He said they were about to leave when his son saw something in the air. "My son mentioned that there was a boat that was having a barbecue on the back," he said. Jacksonville father and son race to the rescue Little did he know, there was a fire on the boat with five people and their dog onboard. "As I looked, I didn't quite see a barbecue, what I saw seemed like engine smoke and then shortly afterwards we saw fire coming from the stern of their boat," Shillingford said. He and his son immediately rushed over to help. "I could see the family was huddled up on the bow of their boat," Shillingford said. As they got closer, Shillingford said he realized they had to keep their distance because the fire was spreading. "So I threw out a stern line and the family with their life vests were able to jump in the water and grab the line and allow me to pull them away from the boat," he said. Shillingford said every family member had a life jacket on and so did the dog. A short time later, he said St. John County first responders arrived and put out the fire while making sure the family was safe. "The real thanks that I have are to the family that was prepared and all the officials that were coming. You could hear the sirens, you could hear the helicopters, you knew that help was on the way," he said. No injuries were reported and Florida Fish and Wildlife is investigating the cause of the fire.
Yahoo
4 hours ago
- Yahoo
Boy's quick thinking saves family stranded on Lake Lansing
LANSING, Mich. (WLNS) — An 11-year-old boy is being praised for calling 911, saying his family was stranded on a large inflatable raft on Lake Lansing. Deputies say it happened shortly after 1:40 p.m. on July 5, 2025. The boy told the Deputies that his mom, another adult, and two children were on the raft, and he was concerned because they couldn't reach shore and the raft was taking on water. Only one person was wearing a life vest. Marine Patrol assisted the Ingham County Sheriff's Office and thanked the 11-year-old for remaining calm and clear when he spoke to dispatchers about where he was and what he needed. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
6 hours ago
- Medscape
Multiomics Platform May Guide Melanoma Treatment
TOPLINE: The novel Tumor Profiler (TuPro) project, which analyzed melanoma samples using nine independent technologies, demonstrated feasibility in guiding treatment decisions. Molecular tumor board recommendations on the basis of TuPro were deemed useful in 75% of cases. METHODOLOGY: Despite advances in melanoma therapy, many patients experience relapse and lack effective treatment options. Multiomics and single-cell profiling promise comprehensive tumor insights but require evaluation for feasibility and clinical utility in guiding treatment decisions. Researchers conducted a prospective, multicentric observational project (TuPro) enrolling 116 patients with any subtype of melanoma, from whom 126 biopsy samples were collected at three Swiss hospitals from January 2019 to November 2020. The TuPro application cohort included 93 patients (103 biopsy samples). The biopsies were analyzed using nine independent technologies, including single-cell genomics, transcriptomics (single-cell RNA sequencing [scRNA-seq]), targeted proteomics (imaging mass cytometry [IMC]), drug phenotyping (Pharmacoscopy), and digital pathology, which generated up to 500 Gb of data per sample within a 4-week turnaround time. The molecular tumor board evaluated data from all technologies to inform treatment recommendations across three patient groups: adjuvant setting (n = 13), palliative standard of care (n = 45), and palliative beyond standard of care (n = 37). The median follow-up duration was 20.5 months. TAKEAWAY: Patients in the palliative standard-of-care group achieved an objective response rate of 60% and a disease control rate of 62%, whereas those in the palliative beyond standard-of-care group achieved an objective response rate of 38% and a disease control rate of 54%. In a matched analysis of patients who received at least three treatment lines, the median progression-free survival reached 8.34 months in the TuPro cohort vs 2.0 months in the non-TuPro cohort (adjusted hazard ratio, 0.23; 95% CI, 0.07-0.79; adjusted P = .0201), suggesting benefit in heavily pretreated patients. Molecular data from TuPro were considered useful by the multidisciplinary molecular tumor board in 75% of evaluated cases, representing a 39% and 33% increase in concordance vs standard clinical workup alone (diagnostic levels 1 and 2, respectively). The TuPro workflow led to actual therapies in 87% of cases. A minimal set of four technologies (next-generation DNA sequencing [NGS], IMC, Pharmacoscopy, and scRNA-seq) could cover all 54 markers used for treatment decision-making at 1.15-fold higher costs than those for the standard NGS for adjuvant or palliative standard-of-care settings and 1.8-fold higher costs than those for the palliative beyond standard-of-care setting. IN PRACTICE: 'This study demonstrates the feasibility of using advanced multiomics approaches, including spatial proteomics, to guide therapy decisions in late-stage melanoma — one of the most aggressive and treatment-resistant cancers — with a reproducible patient benefit,' said Stéphane Chevrier, PhD, CSO, and cofounder of Navignostics and contributor to the TuPro study, in a press release. 'This is a major step toward pan-cancer diagnostics. By providing a comprehensive view of the tumor biology, the approach could eventually identify features that are predictive for treatments across cancer indications.' SOURCE: The study, led by Nicola Miglino, the University of Zurich and University Hospital, Zurich, Switzerland, was published online in Nature Medicine. LIMITATIONS: The current approach of selecting markers for treatment decisions by human experts did not capture all potentially relevant information. The retrospective comparison between TuPro and non-TuPro cohorts limited extrapolation and generalizability of the results. Additionally, definitive conclusions about the clinical value of serial sampling cannot be drawn owing to heterogeneous results and a small sample size. DISCLOSURES: The study received an open-access funding from the University of Zurich. Several authors reported having advisory roles or receiving research funding and having other ties with various pharmaceutical companies. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
